v3.26.1
Schedule of Consolidated Balance Sheet (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Cash and cash equivalents $ 13,217 $ 20,437  
Grants receivable [1] $ 882 [1]
Prepaid expenses and other current assets 433 513  
Property and equipment, net 117 90  
Operating lease right-of-use asset, net 547 641  
Total assets 63,740 71,976  
Accrued expenses 95 72  
Due to affiliates 13 64  
Operating lease liabilities 609 711  
Total liabilities 3,161 1,903  
Paid-in-capital 80,493 68,721  
Accumulated deficit (19,803) 1,442  
Total equity 60,579 70,073 $ 37,321
Total liabilities and equity $ 63,740 71,976  
Exozymes [Member]      
Cash and cash equivalents   68  
Grants receivable   701  
Prepaid expenses and other current assets   441  
Deferred IPO Costs   550  
Property and equipment, net   710  
Operating lease right-of-use asset, net   1,366  
Total assets   3,836  
Accounts payable   851  
Accrued expenses   241  
Due to affiliates   5,479  
Deferred grant reimbursement   130  
Operating lease liabilities   1,417  
Total liabilities   8,118  
Common shares    
Paid-in-capital   4,120  
Accumulated deficit   (8,402)  
Total equity   (4,282)  
Total liabilities and equity   $ 3,836  
[1] In 2024, eXoZymes was deconsolidated from the Company’s consolidated financial statements. As all grant-related costs were associated with eXoZymes, no grant-related figures are reported for 2024.